EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a diagnostic biomarker panel for early-stage lung adenocarcinoma using serum-derived small RNAs

Daisuke Ueda, Ryou-U Takahashi iD, Yasuhiro Tsutani iD, Yukie Nishiyama, Yumiko Koi, Yuta Ibuki, Yoshihiro Miyata, Tomoyuki Akita, Junko Tanaka, Morihito Okada, Hidetoshi Tahara iD

PLOS One · 16.11.2026 · 21 (11) · e0362879

DOI: 10.1371/journal.pone.0362879 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 16.11.2026. Verfasst von Daisuke Ueda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Biomarkers, Tumor, Lung Neoplasms, MicroRNAs. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: New Energy and Industrial Technology Development Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Circulating small RNAs, such as microRNAs (miRNAs) and transfer RNA fragments (tRFs), reportedly reflect the physiological and pathological conditions in various diseases. Herein, we aimed to identify circulating small RNAs for the early diagnosis of lung adenocarcinoma.

Methods

This study included 40 healthy controls and 43 patients with lung adenocarcinoma. We analyzed their serum using small RNA sequencing and identified differentially expressed small RNAs between healthy controls and patients with lung adenocarcinoma. We verified the expression profiles of these small RNAs in 29 patients with lung adenocarcinoma and 27 healthy controls. Finally, we evaluated our current results by performing machine learning-based analysis.

Results

The expressions of two mature miRNAs (miR-193a-5p, miR-423-5p), one miRNA isoform (isomiR) (miR-423-5p(21nt)), and two tRFs (tRF-Gly(CCC)(29nt), tRF-Gly(CCC)(30nt)) were significantly elevated in patients with lung adenocarcinoma than in healthy controls. Moreover, the expressions of one miRNA (miR-20a-5p) and five tRFs (tRF-iMet(CAT)(31nt), tRF-Lys(CTT), tRF-iMet(CAT)(30nt), tRF-iMet(CAT)(29nt), tRF-Val(AAC)) were significantly decreased in patients with lung adenocarcinoma than in healthy controls (area under the curve [AUC] values = 0.71 to 0.85, respectively). Furthermore, a combination of six small RNAs (miR-193a-5p, miR-423-5p(21nt), miR-20a-5p, tRF-Gly(CCC)(29nt), tRF-iMet(CAT)(29nt), and tRF-Val(AAC)) was useful for developing a biomarker panel for the early diagnosis of lung adenocarcinoma. Discovery screening revealed that the panel demonstrated a sensitivity of 0.954 and a specificity of 0.925 (AUC = 0.974), whereas the validation data demonstrated a sensitivity of 0.690 and a specificity of 0.926 (AUC = 0.924).

Conclusion

Serum-derived small RNAs are associated with the status of patients with lung adenocarcinoma, and evaluating small RNAs in serum is a promising non-invasive approach for diagnosing lung adenocarcinoma at an early stage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungBiomarkers, TumorLung NeoplasmsMicroRNAsHumansFemaleMaleMiddle AgedAgedCase-Control StudiesEarly Detection of CancerRNA, TransferNeoplasm StagingGene Expression Regulation, Neoplastic

Substanzen

Biomarkers, TumorMicroRNAsRNA, TransferMIRN193 microRNA, human

Autor:innen und Institutionen

  • Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Department of Cellular and Molecular Biology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Collaborative Laboratory of Liquid Biopsy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • The Research Center for Drug Development and Biomarker Discovery, Hiroshima University, Hiroshima, Japan.

ORCID-Profile: Ryou-U Takahashi, Yasuhiro Tsutani, Hidetoshi Tahara

Förderung

  • New Energy and Industrial Technology Development Organization

Zitieren

APA

Ueda, D., Takahashi, R. U., Tsutani, Y., Nishiyama, Y., Koi, Y., Ibuki, Y., Miyata, Y., Akita, T., Tanaka, J., Okada, M., & Tahara, H. (2026). Development of a diagnostic biomarker panel for early-stage lung adenocarcinoma using serum-derived small RNAs. PLOS One, 21(11), e0362879. https://doi.org/10.1371/journal.pone.0362879

Vancouver

Ueda D, Takahashi RU, Tsutani Y, Nishiyama Y, Koi Y, Ibuki Y, et al. Development of a diagnostic biomarker panel for early-stage lung adenocarcinoma using serum-derived small RNAs. PLOS One. 2026;21(11):e0362879. doi:10.1371/journal.pone.0362879

BibTeX
@article{Ueda2026,
  author = {Ueda, Daisuke and Takahashi, Ryou-U and Tsutani, Yasuhiro and Nishiyama, Yukie and Koi, Yumiko and Ibuki, Yuta and Miyata, Yoshihiro and Akita, Tomoyuki and Tanaka, Junko and Okada, Morihito and Tahara, Hidetoshi},
  title = {Development of a diagnostic biomarker panel for early-stage lung adenocarcinoma using serum-derived small RNAs},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {11},
  pages = {e0362879},
  doi = {10.1371/journal.pone.0362879}
}
Kostenlos starten →